[Corrigendum] Targeting cysteine‑rich angiogenic inducer‑61 by antibody immunotherapy suppresses growth and migration of non‑small cell lung cancer
- Authors:
- Published online on: May 11, 2022 https://doi.org/10.3892/etm.2022.11365
- Article Number: 438
-
Copyright : © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
Article
Exp Ther Med 16:[Related article:] 730–738, 2018; DOI: 10.3892/etm.2018.6274
Following the publication of this paper, it was drawn to the attention of the Editorial Office by a concerned reader that the western blots featured in Fig. 4C and E on p. 736 appeared to have been misplaced, or were possibly mislabelled. After having asked the authors for an explanation to account for the problematic appearance of this figure, they realized that errors were made during the compilation of this figure, and supplied a new version of this figure to the office containing new data which rectifies the problems that were identified. The new version of Fig. 4 is shown below. All the authors agree with the publication of this corrigendum, and thank the Editor of Experimental and Therapeutic Medicine for allowing them the opportunity to publish this. Furthermore, they apologize to the readership for any inconvenience caused.